Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University

by Mbio2018|Published June 1, 2018

Manhattan BioSolutions, Inc. Selected to be Featured in New York Pavilion at BIO International Convention

New York City, New York May 22, 2023 (Issuewire.com) – Manhattan BioSolutions, Inc. (“Manhattan Bio”), an emerging biotechnology company developing new classes of precision […]

Published August 12, 2022

Manhattan BioSolutions, Inc. Signs Commercial Evaluation License Agreements with the National Institutes of Health (NIH) for Use of Monoclonal Antibodies in Novel Antibody-Drug Conjugate (ADC) Oncology Programs

NEW YORK, NY / ACCESSWIRE / July 20, 2022 / Manhattan BioSolutions, Inc. today announced it has entered into two commercial evaluation license […]

Published September 1, 2018

Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball= Project Number: 1R43CA228746-01A1 Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER

Published March 2, 2021

Manhattan BioSolutions Announces Positive Preclinical Data Validating its Novel Synthetic Microbial Therapeutic Platform

New York City, New York Feb 23, 2021 (Issuewire.com) – Manhattan BioSolutions, Inc, an emerging biotechnology company focused on the discovery of immunoregulatory therapies […]